中国全科医学 ›› 2023, Vol. 26 ›› Issue (17): 2155-2161.DOI: 10.12114/j.issn.1007-9572.2022.0904

• 论著·中医研究 • 上一篇    下一篇

刮痧联合药物治疗原发性帕金森病的短期临床疗效研究

王秋琴1, 章雨桐1, 徐语晨1, 柏亚妹1, 陈华1, 姜荣荣1, 严姝霞1, 王庆1, 徐桂华1,*(), 谢颖2, 乔春2, 杨娟3   

  1. 1.210023 江苏省南京市,南京中医药大学护理学院
    2.210022 江苏省南京市中医院脑病科
    3.210029 江苏省南京市,江苏省人民医院神经内科
  • 收稿日期:2022-12-02 修回日期:2023-01-15 出版日期:2023-06-15 发布日期:2023-02-23
  • 通讯作者: 徐桂华

  • 作者贡献:徐桂华提出选题方向;王秋琴、徐桂华进行研究方案设计与项目管理;王秋琴、章雨桐、徐语晨负责研究方案实施;柏亚妹、严姝霞参与研究方案讨论和方法学评估;陈华、姜荣荣、王庆负责收集和录入数据;谢颖、乔春、杨娟负责临床干预质量控制;王秋琴对数据进行统计分析,撰写论文初稿;徐桂华负责文章的质量控制及审校,对文章整体负责;所有作者确认了论文的最终稿。
  • 基金资助:
    江苏省高等学校自然科学研究面上项目(19KJB360014)——基于NF-κB信号通路探讨铜砭刮痧治疗帕金森病的机制研究; 世界中医药学会联合会护理专业委员会开放课题项目(SZLHLA-1906)——铜砭刮痧治疗帕金森病的临床疗效观察; 江苏高校护理学优势学科建设工程资助项目(2019YSHL016)——基于NF-κB信号通路探讨铜砭刮痧治疗帕金森病的机制研究

Short-term Clinical Effect of Guasha Combined with Drug Therapy on Idiopathic Parkinson's Disease

WANG Qiuqin1, ZHANG Yutong1, XU Yuchen1, BAI Yamei1, CHEN Hua1, JIANG Rongrong1, YAN Shuxia1, WANG Qing1, XU Guihua1,*(), XIE Ying2, QIAO Chun2, YANG Juan3   

  1. 1. School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China
    2. Department of Encephalopathy, Nanjing Hospital of Traditional Chinese Medicine, Nanjing 210022, China
    3. Department of Neurology, Jiangsu Province Hospital, Nanjing 210029, China
  • Received:2022-12-02 Revised:2023-01-15 Published:2023-06-15 Online:2023-02-23
  • Contact: XU Guihua

摘要: 背景 帕金森病(PD)作为常见的神经退行性疾病之一,因药物治疗不良反应明显,且长期使用疗效降低,使其成为全球医疗难题。刮痧是应用广泛的中医非药物疗法之一,在神经系统疾病治疗中具有独特优势。目前有关刮痧联合药物治疗原发性PD的研究尚少。 目的 观察刮痧联合药物治疗原发性PD的短期临床疗效。 方法 采用目的性抽样法,选取2021年3—9月在南京市中医院和江苏省人民医院PD门诊诊治的16例原发性PD患者为观察组,按照性别、年龄、病程及Hoehn-Yahr分期相匹配的原则,选择16例原发性PD患者作为对照组。观察组采用刮痧联合西药口服治疗,4周为1个疗程,3个疗程后停止刮痧,单纯西药继续治疗1个疗程作为随访。对照组采用单纯西药口服治疗,4周为1个疗程,治疗4个疗程,最后1个疗程作为随访。治疗3个月和随访1个月,观察统一帕金森病评定量表第三部分(MDS-UPDRS Ⅲ)评分、非运动症状量表(NMSS)评分、临床疗效;治疗3个月观察血清白介素1β(IL-1β)、核转录因子κB(NF-κB)水平。 结果 治疗3个月,两组患者MDS-UPDRS Ⅲ、NMSS评分及血清IL-1β、NF-κB水平均低于组内治疗前(P<0.05);随访1个月,两组患者MDS-UPDRS Ⅲ、NMSS评分均低于组内治疗前(P<0.001);随访1个月对照组患者MDS-UPDRS Ⅲ评分低于组内治疗3个月(P<0.001);随访1个月观察组患者NMSS评分高于组内治疗3个月(P=0.002)。观察组患者治疗3个月、随访1个月MDS-UPDRS Ⅲ、NMSS评分低于对照组(P<0.05)。观察组治疗后IL-1β、NF-κB水平均低于对照组(P<0.05)。治疗3个月及随访1个月,观察组患者临床疗效均优于对照组(Z值分别为-3.651、-3.468,P<0.05)。 结论 刮痧联合药物治疗早、中期原发性PD安全可行,能够改善PD患者的部分运动功能障碍,减轻非运动症状,可明显提高临床疗效,其远期疗效有待开展大样本、多中心的研究进一步探索。

关键词: 帕金森病, 刮痧疗法, 药物疗法, 疗效比较研究, 中医非药物疗法

Abstract:

Background

Parkinson's disease (PD) , as one of the most common neurodegenerative diseases, has become a global medical problem due to the obvious adverse reaction of drug treatment and the reduced efficacy of long-term use. Guasha is one of the widely used non-drug therapies of traditional Chinese medicine (TCM) with unique advantages in the treatment of nervous system diseases. At present, there are few studies on the treatment of idiopathic PD with Guasha combined with drug therapy.

Objective

To explore the short-term clinical effect of Guasha combined with drug therapy for idiopathic PD.

Methods

Sixteen patients with idiopathic PD in the early and middle stages selected by the purposive sampling method from March 2021 to September 2021 in outpatients of Nanjing Hospital of Chinese Medicine and Jiangsu Province Hospital were selected as the observation group, and another 16 patients with idiopathic PD were selected as the control group according to the principle of matching gender, age, course of disease and Hoehn-Yahr stage. The observation group was treated with Guasha combined with western medicine orally for 4 weeks as a course of treatment; after 3 courses of treatment, Guasha was stopped and western medicine orally continued for 1 course of treatment as follow-up. The control group was treated with simple western medicine orally for 4 weeks as a course of treatment, and the last one of 4 courses of treatment was recorded as follow-up. After 3 months of treatment and 1 month of follow-up, the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleⅢ (MDS-UPDRSⅢ) score, Non-motor Symptom Score (NMSS) and clinical efficacy were observed. The levels of serum interleukin-1β (IL-1β) and nuclear transcription factor κB (NF-κB) were observed after 3 months of treatment.

Results

After 3 months of treatment, the scores of MDS-UPDRS Ⅲ and NMSS, and the levels of serum IL-1β and NF-κB in two groups were lower than those before treatment (P<0.05) . After 1 month of follow-up, the scores of MDS-UPDRS Ⅲ and NMSS in two groups were lower than those before treatment (P<0.001) . The score of MDS-UPDRSⅢ of the control group at 1-month follow-up was lower than that at 3 months (P<0.001) . The score of NMSS of the observation group at 1-month follow-up was higher than that at 3 months (P=0.002) . The scores of MDS-UPDRSⅢ and NMSS in the observation group were lower than those in the control group after 3 months of treatment and 1 month of follow-up, and the differences were all statistically significant (P<0.05) . The levels of serum IL-1β and NF-κB in the observation group were lower than those in the control group after treatment (P<0.05) . After 3 months of treatment and 1 month of follow-up, the clinical efficacy of the observation group was better than that of the control group (Z=-3.651, -3.468, P<0.05) .

Conclusion

It is safe and feasible for Guasha combined with drug therapy in the treatment of idiopathic PD patients at the early and middle stage, which can improve some motor dysfunction and alleviate non-motor symptoms and significantly improve the clinical efficacy. However, its long-term efficacy needs to be further explored by large sample and multi-center studies.

Key words: Parkinson disease, Scraping therapy, Drug therapy, Comparative effectiveness research, Non-drug therapy of traditional Chinese medicine